The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Updates and correlative results from the MANIFEST-2 trial
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, shares an update on the MANIFEST-2 trial (NCT04603495) investigating pelabresib plus ruxolitinib combination therapy versus ruxolitinib monotherapy in patients with JAK inhibitor-naive myelofibrosis (MF). The combination therapy led to a significantly greater decrease in spleen volume and a numerically greater decrease in total symptom score (TSS). Additionally, the combination reduced inflammatory cytokines, fibrosis, and megakaryocyte clustering. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting Fees: Incyte Corporation, Celgene/BMS, Blueprint, Abbvie, CTI, Stemline, Galecto, Pharmaessentia, Jubilant, Constellation/Morphosys, Sierra Oncology/GSK, Protagonist, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, Karyopharm; Research Funding: Constellation pharmaceuticals, Ryvu, Zentalis, Stemline Therapeutics, Incyte Corporation.
